Article publishing option Open Access

Limited-Time Complimentary Open Access OfferGet free Open Access by submitting your article on or before March 31st, 2026. This offer applies to general articles only. This journal's open access policy.

Current Psychopharmacology

Indexed in: Cabell's Directory/Journalytics

View All
Aims and Scope:
Current Psychopharmacology publishes peer-reviewed expert reviews, original research articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology. Data must be published for the first time in Current Psychopharmacology.
Read more...
Start Submission Button Icon

Editor-in-Chief:

  • Kenneth Blum Department of Psychiatry
    Western University Health Sciences
    Pomona, CA
    United States of America

ISSN: 2211-5560 (Print)

eISSN: 2211-5579 (Online)

Special Issues With Active Call for Papers

Submission closes on: Jul 10, 2026
Novel Psychiatric Classifications: Challenges, Controversies, and Future Directions

Psychiatric classification systems are at a pivotal crossroads. While traditional taxonomies like the DSM and ICD have provided essential frameworks for diagnosing mental disorders, they have also faced longstanding critiques related to their validity. This special issue, Novel Psychiatric Classifications: Challenges, Controversies, and Future Directions, seeks to explore innovative paradigms in psychiatric nosology. We invite scholars, clinicians, and interdisciplinary researchers to contribute cutting-edge research, theoretical papers, and critical perspectives that address emerging trends and foundational... see more

Guest Editor(s): Dr. Kadir Uludag
Start Submission
Submission closes on: Feb 20, 2026
PD-1 Inhibitors in Neuroprotection: Modulating Neurotransmitter Pathways for Therapy

Programmed cell death protein-1 (PD-1) inhibitors, widely recognized for their role in immunotherapy, have recently emerged as potential neuroprotective agents. Beyond their traditional application in oncology, PD-1 inhibitors influence neuroimmune interactions, impacting neurotransmitter pathways critical for maintaining brain homeostasis. Dysregulation of these pathways is implicated in neurodegenerative and neuropsychiatric disorders, including Parkinson’s disease, Alzheimer’s disease, and depression. By modulating immune responses, PD-1 blockade may reduce neuroinflammation, enhance neuronal survival, and restore neurotransmitter balance. Recent studies... see more

Guest Editor(s): Dr. Prashant Tiwari
Start Submission